1 unknown, 1 withdrawn. 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Unknown 1 |
Follow HORIZANT 300 mg: new trials by email Literature Review of HORIZANT 300 mg trials Research Report on HORIZANT 300 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS HORIZANT 300 mg, HORIZANT 600 mg, Placebo - RLS | Phase 4 | Unknown | XenoPort, Inc. | 132 | 2016-02-01 | 2021-06-09 |
| A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS HORIZANT 300 mg - RLS | Phase 1 | Withdrawn | XenoPort, Inc. | 2016-01-01 | 2021-04-12 |
XenoPort, Inc. (2)
United States (2)
Steven Caras, MD (2)